Loading...
Market
Story
FDA Approves Humacyte's SYMVESS™ for Extremity Vascular Trauma Treatment, First-in-Class Bioengineered Vessel, $HUMA
Dec 20, 2024, 04:12 AM
The U.S. Food and Drug Administration (FDA) has granted approval to Humacyte's SYMVESS™, a novel acellular tissue-engineered vessel designed for the treatment of extremity vascular trauma. This first-in-class bioengineered vessel offers an off-the-shelf alternative to autologous vein grafts, aiming to enhance outcomes in patients with limb-threatening vascular injuries. The approval marks a significant advancement in the field of vascular repair, as it may provide a more accessible treatment option for those affected by traumatic injuries. The announcement has been met with positive reactions from industry observers, highlighting the potential impact of this technology on patient care.
View original story
Similar markets
No major competitors • 25%
1 major competitor • 25%
2 major competitors • 25%
3 or more major competitors • 25%
Yes • 50%
No • 50%
No international approvals • 25%
1 to 2 international approvals • 25%
3 to 4 international approvals • 25%
5 or more international approvals • 25%
Less than $50 million • 25%
$50 million to $100 million • 25%
$100 million to $200 million • 25%
More than $200 million • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Yes • 50%
No • 50%
<10% • 25%
10-25% • 25%
25-50% • 25%
>50% • 25%